Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic and clinical characterization of SPG10: a case series of novel pathogenic variants and phenotypic diversity.

Annals of medicine and surgery (2012)·2025
Same author

Disrupted glycosylphosphatidylinositol anchoring induces ER stress and restricts enterovirus infection.

PLoS pathogens·2025
Same author

Single-cell atlas of human liver and blood immune cells across fatty liver disease stages reveals distinct signatures linked to liver dysfunction and fibrogenesis.

Nature immunology·2025
Same author

SARS-CoV-2 remodels the Golgi apparatus to facilitate viral assembly and secretion.

PLoS pathogens·2025
Same author

HBV promotes epithelial-mesenchymal transition in HCC and liver fibrosis through JNK-mediated autophagy.

Hepatology communications·2025
Same author

Dengue and Zika virus NS4B proteins differ in topology and in determinants of ER membrane protein complex dependency.

Journal of virology·2025

Related Experiment Video

Updated: May 22, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Treating hepatitis C infection by targeting the host.

Shadi Salloum1, Andrew W Tai

  • 1Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.

Translational Research : the Journal of Laboratory and Clinical Medicine
|May 29, 2012
PubMed
Summary

Hepatitis C virus (HCV) infection affects millions globally. Targeting host factors, essential for viral replication, offers a promising complementary strategy to direct-acting antivirals for effective HCV treatment.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Related Experiment Videos

Last Updated: May 22, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Area of Science:

  • Virology and Infectious Diseases
  • Hepatology
  • Drug Discovery and Development

Background:

  • Chronic hepatitis C virus (HCV) infection impacts over 130 million individuals worldwide.
  • HCV can progress to severe liver conditions like cirrhosis, liver failure, and hepatocellular carcinoma.
  • Current direct-acting antiviral (DAA) treatments, while effective, face limitations due to side effects and viral resistance.

Purpose of the Study:

  • To explore host cellular factors as alternative therapeutic targets for hepatitis C.
  • To review host-pathogen interactions that are crucial for the HCV life cycle.
  • To identify attractive host targets for novel antiviral therapies against HCV.

Main Methods:

  • Review of existing scientific literature and studies.
  • Analysis of RNA interference screens identifying essential host factors for HCV.
  • Examination of host-pathogen interactions in the context of HCV replication.

Main Results:

  • Hepatitis C virus relies on numerous host cellular proteins for its life cycle.
  • RNA interference screens have identified a significant number of these essential host factors.
  • Understanding these host-HCV interactions is key to developing new therapeutic strategies.

Conclusions:

  • Targeting host cellular factors presents a viable complementary strategy to direct-acting antivirals for HCV.
  • Identifying and validating these host factors can lead to the development of novel treatments with potentially higher genetic barriers to resistance.
  • Further research into host-HCV interactions is crucial for advancing hepatitis C therapy.